Search Result
Results for "
(-)-Isoproterenol
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0468
-
|
Isoproterenol hydrochloride
|
Adrenergic Receptor
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
|
Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .
|
-
-
- HY-B1670A
-
|
Levisoprenaline hydrochloride; Proternol L hydrochloride
|
Caspase
TNF Receptor
|
Metabolic Disease
|
|
(-)-Isoproterenol (Levisoprenalinel) hydrochloride is the R-isomer of Isoproterenol. (-)-Isoproterenol hydrochloride can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol hydrochloride can be used for the study of diabetic retinopathy .
|
-
-
- HY-158426
-
2-APQC
1 Publications Verification
|
Sirtuin
|
Cardiovascular Disease
|
|
2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
|
-
-
- HY-101016
-
17-ODYA
1 Publications Verification
|
Cytochrome P450
Apoptosis
|
Cardiovascular Disease
|
|
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-14895
-
|
CM346
|
Parasite
Monoamine Oxidase
Sigma Receptor
P-glycoprotein
|
Infection
Cardiovascular Disease
Neurological Disease
|
|
Fabomotizole (CM346) is an insecticide with anxiolytic, antianxiety, and neuroprotective activities and a substrate of p-glycoprotein. Fabomotizole inhibits the ST-segment depression induced by isoproterenol in a rat model of acute subendocardial ischemia. Fabomotizole also inhibits Giardia lamblia and has the potential to inhibit giardiasis. Fabomotizole also targets Sigma1R, NRH:quinone reductase 2 (NQO2), and MAO-A to exert anxiolytic effects .
|
-
-
- HY-116152
-
|
Ciprofol; HSK3486
|
GABA Receptor
Sirtuin
Keap1-Nrf2
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Cipepofol (Ciprofol), a novel 2,6-disubstituted phenol derivative, is a positive allosteric modulator and direct agonist of the GABAA receptor. Cipepofol can cause the central nerve inhibition and promote sleep based on the structural modification of Propofol (HY-B0649). Cipepofol can activate the sirtuin1 (Sirt1)/Nrf2 pathway. Cipepofol protects the heart against Isoproterenol (ISO; HY-B0468)-induced myocardial infarction by reducing cardiac oxidative stress, inflammatory response and cardiomyocyte apoptosis .
|
-
-
- HY-N0353
-
|
(+)-Curdione
|
Ferroptosis
Apoptosis
Reactive Oxygen Species (ROS)
Autophagy
Glutathione Peroxidase
Keap1-Nrf2
Heme Oxygenase (HO)
TGF-β Receptor
Indoleamine 2,3-Dioxygenase (IDO)
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression .
|
-
-
- HY-107580
-
|
|
GPR109A
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC50 of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis .
|
-
-
- HY-B1670
-
|
Levisoprenalinel; Proternol L
|
Caspase
TNF Receptor
|
Metabolic Disease
|
|
(-)-Isoproterenol (Levisoprenalinel) is the R-isomer of Isoproterenol. (-)-Isoproterenol can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol can be used for the study of diabetic retinopathy .
|
-
-
- HY-106718
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Barucainide is an Ib-class anti-arrhythmic agent (moderately blocking sodium channel). Barucainide exhibits concentration-dependent inhibitory effects on the maximum upstroke velocity (Vmax) of Purkinje fibers and ventricular muscle in dogs. Barucainide significantly shortens the action potential duration (APD). Barucainide significantly inhibits the pacemaker activity frequency of atrial tissue in rabbits and the enhanced automaticity of Purkinje fibers under normal resting potential in response to isoproterenol. Barucainide cannot inhibit the abnormal automaticity emission frequency of canine Purkinje fibers induced by barium. Barucainide can be used for research on arrhythmias .
|
-
-
- HY-Z7733
-
|
Desmethylcarvedilol; BM-14242
|
Calcium Channel
|
Metabolic Disease
|
|
O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 R4496C) mutation (IC50 = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 µg/kg, respectively) .
|
-
-
- HY-122949
-
-
-
- HY-B0468R
-
|
Isoproterenol hydrochloride (Standard)
|
Reference Standards
Adrenergic Receptor
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
|
Isoprenaline (hydrochloride) (Standard) is the analytical standard of Isoprenaline (hydrochloride). This product is intended for research and analytical applications. Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .
|
-
-
- HY-121140
-
|
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in Gi-mediated pathways, but not at those transduced by Gq/G11. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .
|
-
-
- HY-B0468S
-
|
Isoproterenol-d7 hydrochloride
|
Isotope-Labeled Compounds
Endogenous Metabolite
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Isoprenaline-d7 (hydrochloride) is a deuterated labeled Isoprenaline (hydrochloride) . Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .
|
-
-
- HY-108353S
-
-
-
- HY-157976
-
|
dinor-PGE1
|
Endogenous Metabolite
Prostaglandin Receptor
|
Others
|
|
Dinorprostaglandin E1 (dinor-PGE1) is the hepatocyte metabolite of prostaglandin E1 and prostaglandin E. Prostaglandin E1 and prostaglandin E inhibit glucagon, epinephrine, isoproterenol (beta-adrenergic agonist), or epinephrine-stimulated glycogenolysis when co-treated with Isoproterenol (HY-B0468) .
|
-
-
- HY-173005
-
|
|
PI3K
Akt
GSK-3
Apoptosis
|
Cardiovascular Disease
|
|
JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models .
|
-
-
- HY-W416440
-
|
ASL-8123 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Metabolic Disease
|
|
Esmolol acid (ASL-8123) hydrochloride is a weak β-adrenergic receptor antagonist. Esmolol acid hydrochloride inhibits the heart rate and diastolic blood pressure response induced by Isoproterenol (HY-B0468) in a dose-dependent manner and can be used in studies of renal failure .
|
-
-
- HY-117084
-
|
|
Adrenergic Receptor
|
Metabolic Disease
|
|
BMS-210285 is a highly selective agonist for the 3 receptor. BMS-210285 has a Ki of 9 nM at the human 3-adrenoceptor. BMS-210285 possesses a 3 intrinsic activity of 83% relative to isoproterenol. BMS-210285 can be studied for obesity and type 2 diabetes research .
|
-
-
- HY-106088
-
|
LY186655 free acid
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Tibenelast (LY186655) free acid is a potent and orally active is a phosphodiesterase inhibitor. Tibenelast free acid is an anti-asthma agent Tibenelast free acid increases the heart rate response to isoproterenol (HY-108353). Tibenelast free acid shows anti-anaphylactic shock activity. Tibenelast free acid has the potential for the research of asthma and other respiratory diseases .
|
-
-
- HY-106684
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ridazolol is a β-adrenergic receptor (βAR) antagonist. Ridazolol exhibits a high degree of selectivity for β-1 adrenergic receptor (β1AR) and possesses moderate intrinsic sympathomimetic activity (ISA). Ridazolol can competitively antagonize the relaxation effects induced by isoproterenol. Ridazolol is utilized in the research of cardiovascular diseases .
|
-
-
- HY-108998
-
|
|
Histone Methyltransferase
|
Cardiovascular Disease
|
|
Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts .
|
-
-
- HY-114052
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
NVP-ABE171 is an efficient, long-lasting and orally active PDE4 inhibitor with IC50 values for PDE4D, PDE4B, PDE4A and PDE4C of 1.5, 34, 602 and 1230 nM respectively. NVP-ABE171 enhances the cAMP accumulation induced by isoproterenol, inhibits the oxidative burst of eosinophils and the release of inflammatory cytokines from T cells and monocytes. NVP-ABE171 exhibits potent anti-inflammatory activity in animal models of asthma and pulmonary inflammation. NVP-ABE171 can be used for research on asthma and chronic obstructive pulmonary disease .
|
-
-
- HY-101016R
-
|
|
Reference Standards
Cytochrome P450
Apoptosis
|
Cardiovascular Disease
|
|
17-ODYA (Standard) is the analytical standard of 17-ODYA. This product is intended for research and analytical applications. 17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes[1][2][3]. 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-166478S
-
|
Desmethylcarvedilol-d5; BM-14242-d5
|
Isotope-Labeled Compounds
Calcium Channel
|
Metabolic Disease
|
|
O-Desmethyl carvedilol-d5 (Desmethylcarvedilol-d5) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 R4496C) mutation (IC50 = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 μg/kg, respectively) .
|
-
-
- HY-N0353R
-
|
(+)-Curdione (Standard)
|
Reference Standards
Ferroptosis
Apoptosis
Reactive Oxygen Species (ROS)
Autophagy
Glutathione Peroxidase
Keap1-Nrf2
Heme Oxygenase (HO)
TGF-β Receptor
Indoleamine 2,3-Dioxygenase (IDO)
|
Others
|
|
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression .
|
-
-
- HY-149796
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Tazolol is a specific β-adrenergic antagonist (IC50: 700 nM for (-) isoproterenol-elicited accumulation of cyclic AMP in rat cortical slices). Tazolol produces a significant and sustained increase in cardiac output and stroke volume. Tazolol can be used in the research of heart failure .
|
-
-
- HY-106684A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ridazolol hydrochloride is a β-adrenergic receptor (βAR) antagonist. Ridazolol hydrochloride exhibits a high degree of selectivity for β-1 adrenergic receptor (β1AR) and possesses moderate intrinsic sympathomimetic activity (ISA). Ridazolol hydrochloride can competitively antagonize the relaxation effects induced by isoproterenol. Ridazolol hydrochloride is utilized in the research of cardiovascular diseases .
|
-
-
- HY-114833
-
|
(Rac)-Bunolol; dl-Bunolol
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Bunolol ((Rac)-Bunolol) is a β-adrenergic receptor blocker. Bunolol antagonizes the β-receptor agonist activity induced by Isoproterenol (HY-B0468) and Dichloroisoproterenol. Bunolol reduces the heart rate and mean blood pressure of anesthetized dogs. Bunolol decreases spontaneous motor activity and Amphetamine-induced hyperactivity in rats, potentiates Pentobarbital-induced hypnosis in mice, and protects rats from extensor tonic convulsions induced by maximal electroshock .
|
-
-
- HY-183859
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
H142/08 is a β1-adrenergic receptor-selective agonist. H142/08 induces concentration-dependent relaxation of isolated rat uterus and acts as a chronotropic stimulant to increase atrial rate, and its effects are effectively antagonized by Pafenolol (HY-165495). H142/08 also antagonizes the chronotropic effect of isoproterenol on isolated rat right atrium, but requires a higher proportion of receptor occupancy to produce sufficient stimulatory effects .
|
-
-
- HY-182635
-
|
|
Adrenergic Receptor
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
ICI 147798 is an orally effective β-adrenoceptor antagonist with a pKB of 9.1 (in guinea pig right atrium) and 8.8 (in guinea pig trachea). ICI 147798 acts as a diuretic and intraocular pressure-lowering agent. ICI 147798 blocks β-adrenoceptors, inhibits isoproterenol-induced tachycardia and vasodepressor responses, exhibits slowly dissociating, insurmountable antagonism against β1-adrenoceptors, and shows surmountable competitive antagonism against β2-adrenoceptors. ICI 147798 induces natriuresis and kaliuresis, inhibits sodium transport, and reduces intraocular pressure .
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0468S
-
|
|
|
Isoprenaline-d7 (hydrochloride) is a deuterated labeled Isoprenaline (hydrochloride) . Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .
|
-
-
- HY-108353S
-
|
|
|
Isoprenalin-d7 acetate is an internal standard for the determination of isoproterenol by GC- or LC-MS .
|
-
-
- HY-166478S
-
|
|
|
O-Desmethyl carvedilol-d5 (Desmethylcarvedilol-d5) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 R4496C) mutation (IC50 = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 μg/kg, respectively) .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-101016
-
17-ODYA
1 Publications Verification
|
|
Alkynes
|
|
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: